Ask the expert: How will Brexit affect Parkinson’s drugs and research?
Author: Simge Eva DoganPublished: 30 January 2020
Prep: Cook: Serves:
The UK is due to
formally leave the European Union this week. In the second in our series where
we ask experts about the biggest issues facing the Parkinson’s community, Dr
Kieran Breen of the European Medicines Agency Committee for Advanced Therapies gives
his views on the likely impact of Brexit – from the availability of Parkinson’s
medication to international research collaboration
First of all, could you explain to our readers how
Brexit might affect people with Parkinson’s? Will there be an impact on the
supply of medications?
It’s very difficult to look into the future, but yes, the
availability of the therapies and drugs for people with Parkinson’s may be
impacted. We don’t know how things are going to develop in the transition period
over the next 11 months, but it could be that when drugs are coming through
customs they are delayed at the point of entry to the country.
I would imagine that because pharmaceuticals are so
important to the lives of people in the UK with Parkinson’s and every other
condition, that the manufacturing standards are going to stay the same here as
with the rest of Europe.
What might happen to Parkinson’s drugs manufacturing in
At the moment, within Europe, the quality of drug
manufacture is the same throughout the 28 countries. The manufacturing is
usually assessed at a local level, so in the UK that would be the Medicines and
Healthcare products Regulatory Agency (MHRA), which is responsible for drug
If the MHRA assess and approve a drug at a manufacturing
site, it can go anywhere to 28 countries. However, come Brexit, what will
happen is that will no longer be the case. Any drugs manufactured in the UK
cannot automatically be sent to the 27 countries and vice versa.
Theoretically what would happen in the case of a hard Brexit is somebody from the UK will have to go to wherever the drug is manufactured and assess the quality of the manufacturing process. It’s unlikely that this will happen, but it’s a possibility.
Will Brexit impact Parkinson’s drug trials?
Once the UK is no longer in the EU, it will be less likely
that drug trials will be carried out in the UK, because the agreed standards may
be different. Also, if companies want to license a new drug, will they submit
the marketing authorisation application to the European Medicines Agency (EMA),
which is around 600 million people, or submit it to the UK, which is 60 million
people? Well, it’s a no brainer that companies are more likely to submit to the
EU funding supports a substantial amount of medical research in the UK. What effect do you think that Brexit will have for the future of Parkinson’s research and innovation in the UK?
There are two sources of funding
in the UK for Parkinson’s research – charity funding and government funding.
With government funding you can never tell what’s going to come up by the next
budget, but UK charities will continue to fund research. I don’t think Brexit
will have a significant impact on that.
The main area where there is
going to be a problem is European research funding. The European Commission
I don’t know off-hand how much of that goes to Parkinson’s.
Once Brexit happens, UK
researchers will no longer have access to EU funding, so it will choke off the
finance but it will also provide a barrier to international interaction. Interacting
with other people and exchanging ideas is a really important part of research. International
collaboration facilitates the development of new therapies, treatments,
diagnostic models and really increases the understanding of Parkinson’s.
What’s your advice for people in the Parkinson’s
community wondering how best to prepare for these changes?
With Brexit, who knows what’s going to happen? Patient organisations and patients’ collaborators need to
keep a very close eye on what’s happening from a Brexit perspective and make
sure they are talking to the right people so that their voices are heard.
Patients and healthcare professionals need to work with organisations to make sure that the agenda is moved forward – and make sure that MPs are aware of the implications of Brexit from a patient’s perspective. It’s really important that the topic of drug availability remains on the agenda.
Need to know: Dr Kieran Breen is a UK-based pharmacologist. He worked at Parkinson’s UK for nine years as Director of Research & Innovation. He was nominated by the EPDA to join the European Medicines Agency Committee for Advanced Therapies in 2013 – a group which deals with the next generation of therapies.
At a glance: Parkinson’s and Brexit
Brexit may affect the availability of Parkinson’s therapies and drugs in the UK.
It will be less likely that drug trials are carried out in the UK after Brexit.
After Brexit, UK researchers will no longer have access to EU funding which may affect both the financing of new studies and international collaboration.
Parkinson’s organisations need to make sure that patient voices are heard during the transition and lobby the government to ensure that drug availability remains on the agenda.
Throughout hot summer months why not serve a refreshing gazpacho
6 days ago
Research offers new insights on a cause of Parkinson’s disease
Researchers in Denmark have shared insights on a cause of up to 95% of Parkinson’s disease cases. Using data on gene patterns and three mouse models, scientists at the University of Copenhagen found that a blockage to a pathway regulating mitochondria (‘powerhouses’ that generate energy for reactions in cells) causes a form of the condition known as ‘sporadic Parkinson’s disease’. When the pathway becomes blocked by a protein, damaged mitochondria accumulate, unable to produce enough energy – which in turn causes nerve cells to die. “Just like when people eat, cells take what they need and get rid of … waste products,” explained corresponding study author Professor Shohreh Issazadeh-Navikas. “But if our brain cells have this specific kind of signalling blockage, it means that the powerhouse of the cell – mitochondria – cannot get cleaned up after being damaged.” The team now plan to investigate the pathway’s role in neuronal…
Dance training with music could help slow the progression of mild-to-moderate Parkinson’s disease, researchers at York University in Canada have found. As part of the study, the researchers followed 16 participants with Parkinson’s disease who attended weekly dance classes between 2014 and 2017. The research team compared them to 16 people with Parkinson’s who did not take part in the classes. The research team found that the motor and non-motor symptoms of those who took part in the dance classes improved or did not progress over time – while those who did not participate showed a continual decline. “Dance is so complex,” said study author, PhD candidate Karolina Bearss. “It’s a multi-sensory type of environment. It incorporates and stimulates your auditory, tactile, visual and kinaesthetic senses and adds an interactive social aspect. Regular exercise does not offer these aspects. There’s so much more to dance.”
Vineyard pesticides may be linked to Parkinson’s disease
Exposure to pesticides used in vineyards could be linked to an increased risk of Parkinson’s disease, according to researchers in France. As part of their study, the team used a health insurance database to identify farmers in France who had been diagnosed with the condition. They then compared these records with data combining an agriculture census and pesticide expenditures across regions of varying farming types, including vineyards. They found that areas with vineyards that lacked designation of origin, and spent the most on pesticides, were associated with a 16% higher incidence of Parkinson’s. “This result suggests that agricultural practices and pesticides used in these vineyards may play a role in Parkinson’s disease,” the researchers concluded, “and that farmers in these farms should benefit from preventive measures aiming at reducing exposure.”